Repligen Corp.(NASDAQ : RGEN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|MRK||Merck & Co., Inc.||-0.06%||81.12||0.7%||$1566.02m|
|JNJ||Johnson & Johnson||0.19%||163.71||0.7%||$997.82m|
|BMY||Bristol-Myers Squibb Co.||-0.38%||57.59||1.0%||$625.23m|
|LLY||Eli Lilly & Co.||1.07%||243.75||1.1%||$585.84m|
|AVIR||Atea Pharmaceuticals, Inc.||-0.16%||12.73||0.3%||$125.28m|
|NVO||Novo Nordisk A/S||1.51%||105.99||0.1%||$89.92m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||2.27%||139.98||0.0%||$52.50m|
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.